BioSpace News Archive

NantKwest, Inc., a clinical-stage, natural killer cell-based therapeutics company, announced the pricing of an underwritten public offering of an aggregate of 7,410,000 shares of its common stock.

Moberg Pharma AB announces that MOB-015 met the primary endpoint in the European Phase 3 study including 452 onychomycosis patients, showing non-inferiority versus topical ciclopirox.

Complementary expertise provides a single vendor solution to streamline data workflows from ‘instrument to insight’, boosting research efficiency

Initiated in late 2019, the Novartis Innovation Prize: Assistive Tech for Multiple Sclerosis (MS) identified and encouraged technology ideas from all over the world with the aim to improve mobility, accessibility and daily life for people living with MS

With this supply, Stevanato Group is playing a key role in the global challenge of scaling up the industrialization of glass vials, a critical component for the delivery of the vaccine

June 25, 2020 10:05 UTC IRVING, Texas--( BUSINESS WIRE )-- Vizient, Inc. today shared data showing a 610% increase in demand by its member hospitals for dexamethasone, a commonly used corticosteroid, in the week since the initial trial results of a clinical study* conducted in the United Kingdom showed it reduced the mortality of patients who are severely ill with COVID-19. As a result of the spike in demand, fill rates for the products are now at 54% for Vizient member hosp

Theravance Biopharma, Inc., a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, announced that the first COVID-19 patient has been dosed in a Phase 2 study of TD-0903.

Myriad Genetics, Inc., a leader in molecular diagnostics and precision medicine, announced that a new study published in Future Medicine demonstrates the ability of myPath® Melanoma to accurately classify skin lesions ruled indeterminate by standard pathological review.

Company expands program to award 25 grants totaling $125,000 to fund nonprofit, community-based organizations supporting individuals with sickle cell disease and beta-thalassemia

BSM Partners, the leading pet care research and consulting firm, calls on their peers in the veterinary, veterinary cardiology, animal nutrition, and related fields to undertake studies that produce appropriately controlled, original research to determine the relationship between canine diets and dilated cardiomyopathy.